Kcl Capital, L.P. Caribou Biosciences, Inc. Transaction History

Kcl Capital, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $101,040 - $183,840	-12,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $41,669 - $66,430	2,856 Added 31.23%	12,000 $181,000
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $144,018 - $276,971	9,144 New	9,144 $218,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $121M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Kcl Capital, L.P., based on Form 13F filings with the SEC.

Stay updated on Kcl Capital, L.P. with notifications on news.